Takeda Oncology Push Pays Off With Ixazomib Breakthrough
This article was originally published in PharmAsia News
Executive Summary
A recent Breakthrough Therapy Designation from the FDA for Takeda's amyloidosis drug ixazomib (MLN9708) provides further evidence of Japanese pharma firms' growing innovative capabilities in oncology.